Greece – Mammography devices – «Προμήθεια Εξειδικευμένου Ιατροτεχνολογικού, Χειρουργικού, Διαγνωστικού και Θεραπευτικού Εξοπλισμού για την Αναβάθμιση των Υπηρεσιών Υγείας του Γενικού Νοσοκομείου Θεσσαλονίκης «Ο Άγιος Δημήτριος»

Greece – Medical consumables – Δ.14/2026

Greece – Chemical reagents – ΠΡΟΜΗΘΕΙΑ ΑΝΤΙΔΡΑΣΤΗΡΙΩΝ ΑΥΤΟΜΑΤΟΥ ΟΡΜΟΝΟΛΟΓΙΚΟΥ & ΙΟΛΟΓΙΚΟΥ ΑΝΑΛΥΤΗ ΜΕ ΣΥΝΟΔΟ ΕΞΟΠΛΙΣΜΟ ΤΩΝ ΚΥ ΒΟΡΕΙΟΥ ΤΟΜΕΑ ΠΑΤΡΩΝ ΚΑΙ ΙΩΑΝΝΙΝΝΩΝ

Greece – Anaesthesia devices – Αρ. Διακήρυξης 010/2026

Greece – Laboratory reagents – 21/ΤΑ/2026 ΤΑΚΤΙΚΟΣ ΑΝΟΙΚΤΟΣ ΔΙΑΓΩΝΙΣΜΟΣ ΑΝΩ ΤΩΝ ΟΡΙΩΝ

Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new…

Expected Impact: The action under this topic is expected to achieve the following impacts: Faster and more informed decision-making through the use of an AI-driven NAM (AI Foundation Toxicology Model) and increased efficiency through rapid processing of vast amounts of data [1] . Increased consistency and standardisation in a NAM-based approach, specifically an AI model, used by industry in the efficient development, testing and production of safe and effective innovative health technologies, improving industrial competitiveness. Regulatory adoption of a NAM-enabled second species waiver model (AI Foundation Toxicology Model) and weight-of-evidence framework, in line with recommendations and more consistent global decision-making on waiving second species testing. Reduction in animal use, accelerated timelines and lower costs, enhancing the competitiveness of the European health industry through economical and ethical benefits. Improved public health as patients will benefit from safe and effective medicines developed faster using validated NAMs. The action is expected to contribute to the EU Directive (2010/63/EU) [2] on the protection of animals used for scientific purposes and…

Expected Outcome: This action will establish a strategic European initiative to develop scalable, modular, and interoperable photonic quantum computing platforms. Proposals for this topic are expected to address and provide credible solutions to at least two major technical roadblocks currently limiting the advancement of photonic quantum computing such as: The lack of deterministic, high-efficiency photonic entanglement and loss-tolerant architectures suitable for fault-tolerant scaling The absence of a standardised, integrated control stack combining photonic hardware, firmware, and system software with reliable benchmarking across platforms Project results are expected to contribute to the following expected outcomes: By 2028, demonstration of a photonic NISQ processor with ≥100 photonic qubits, integrating deterministic single-photon sources, low-loss waveguides, on-chip detectors, and a firmware stack (scheduler, controller, compiler), validated via hardware-agnostic benchmarks and hybrid photonic-HPC applications demonstrating classical-quantum crossover By 2030, delivery of a full-stack, high-connectivity photonic quantum computer, with modular scalability, integrated…

Expected Outcome: Successful proposals will contribute to the Chemicals Strategy for Sustainability and Ecodesign for Sustainable Products Regulation, the Chemical Industry Action Plan, the Clean Industrial Deal as well as the Horizon Europe Mission "Restore our Ocean and Waters by 2030" in particular to Objective 2: "Prevent and eliminate pollution of our oceans, Seas and waters". Projects results are expected to contribute to the following expected outcomes: Full industrial scale biorefinery and related value chain(s) to produce SSbD bio-based solutions for home and/or personal care sector with significantly improved sustainability. Wider availability of bio-based products in home and/or personal care sector meeting both regulatory standards and technical performance requirements. Increased consumer/end user acceptance of bio-based solutions, facilitating market uptake. Contribution to the EU strategic autonomy, resilience and competitiveness, reducing the fossil feedstock dependence for chemicals production and minimising biomass imports dependencies. Scope: The home and personal care sector, including fast-moving consumer goods (FMCG) and cosmetics, is a key industry where…

Expected Outcome: This flagship pilot is the culmination of the entire activity catalogue carried out by the CCAM Partnership since its launch in 2021. It will combine in one project the most promising CCAM use-cases across three key domains, with the technological advancements from all its R&I clusters [1] supporting and enabling CCAM systems and services towards market uptake. This action is expected to contribute to all the following outcomes: Large-scale demonstrations of inclusive, user-oriented, and well-integrated CCAM systems and services for people and goods in mixed traffic through Field Operational Tests (FOTs), Technology Pilots, and Living Labs, building upon advanced and emerging SAE Level 2 systems to move towards SAE Level 3 and 4 functionalities, at multiple test sites and corridors showcasing CCAM potential [2] , for a minimum of 12 months. Validation of enabling technologies that facilitate the extension of Operational Design Domains (ODDs) in large-scale operations and enhance perception performance under poor lighting and adverse weather conditions in large-scale demonstrations and pilots. Assessment of deployment readiness and demonstration of technological…

Expected Outcome: Proposals are expected to contribute to all following points: The projects must fulfil the performance targets, at the cell and system level, corresponding to the specific targeted application, to be specified in the proposal. Appropriate KPI must be defined for the energy density (volumetric and gravimetric), Power density and C-rate, number of cycles and cost defined under operational conditions. Boost EU competitiveness in next-generation battery technologies for mobility applications. Develop pilot manufacturing capability for next generation lithium-based batteries. Strengthen the EU battery value chain, including new manufacturing equipment, automation, and scalable production processes. Advance the understanding of next-generation battery interfaces at an industrial scale, ensuring manufacturability, durability, and cost-effectiveness. In the case of aviation, the battery requirements should be compatible at minimum with EASA CS.23 (level 4), CS.27 and preferably with CS.25 categories. Scope: This topic will support the scaling-up of next generation (i.e., beyond generation 3) lithium-based batteries (e.g., semi and all-solid state, generation5) from cell…